Asian Journal of Research and Reports in Endocrinology

Diabetes is a metabolic disorder occurs due to insulin resistance or due to low production of insulin, this effects the glucose uptake by individual cells which progressively damages the cells or leads to improper functioning. These modifications at cellular levels progressively results in several co-morbidities. There are various medications available for blood glucose control not particular on cellular damages.

JRK’s D-Co-D tablets is a polyherbal medicine that is studied for its role in blood glucose control and organ health improvement. A three arm multi centered clinical observations and outcome are collected for three groups.

Blood glucose related and other organ health indicative parameters against the prescription of JRK’s D-Co-D tablets, a proprietary Siddha drug as an adjuvant to conventional therapy (Metformin +Vildagliptin) was analyzed.  Conventional line of therapy without JRK’s D-Co-D tablets and Madhumeghachoornam instead of JRK’s D-Co-D tablets were kept as control groups. 

Blood glucose related and other parameters (blood and urine) post inclusion of JRK’s D-Co-D tablets as an adjuvant was shown a remarkable improvement when compared to other two groups.  Statistical significance was also established for the above findings. The treatment inclusion of JRK’s D-Co-D tablets clearly indicated significant improvement of various vital organs (functioning) and confirms the role of JRK’s D-Co-D tablets to prevent co-morbidity associated with diabetes mellitus.